Interviews
View More
Quick Q&A: Sarah Klein on scrutinizing PBM contracts

Lockton's Sarah Klein says employers are already asking hard questions about PBM transparency, even though many of the new rules have not taken effect.

Quick Q&A: Jeff Dunn, Pharm.D., MBA, on 340B discounts and PBM rebates

NeosRx CEO Jeff Dunn, Pharm.D., MBA, explains how 340B claims can disadvantage PBMs because of loss of rebates..

Helen Colby on the link between medical bills and anticipated pain

Patients facing higher out-of-pocket costs predicted procedures would hurt more than procedures with no copay, according to the results of a recent Carnegie Mellon study.

Quick Q&A: Benjamin N. Rome, M.D., M.P.H., on the IRA and drug launch prices

Drug launch prices are rising, but Benjamin N. Rome, M.D., M.P.H., and colleagues found no evidence manufacturers raised them in response to the Inflation Reduction Act.

A new paradigm: What oral anti-inflammatory therapy means for prescribers and payers

DPP-1 inhibitors are oral small molecules that block the enzyme responsible for activating neutrophil elastase, and in the pivotal ASPEN trial, brensocatib reduced annualized exacerbations by about 20% versus placebo.

Inside DPP-1 inhibition: A new oral anti-inflammatory mechanism for bronchiectasis

DPP-1 inhibitors are oral small molecules that block the enzyme responsible for activating neutrophil elastase, and in the pivotal ASPEN trial, brensocatib reduced annualized exacerbations by about 20% versus placebo.

Haley B. Naik, M.D., on the hidradenitis suppurativa guideline recommendations most likely to change clinical practice practice

Naik says a strong recommendation for infliximab and a call for routine pain assessment are the HS guideline changes most likely to change clinical practice.

Haley B. Naik, M.D., on why new HS guidelines recommend against radiotherapy for HS in children and teens

New guidelines for care of hidradenitis suppurativa advise against radiotherapy for children and adolescents, citing its long-term risks and safer treatment options.

Haley B. Naik, M.D., M.H.Sc.,on the true prevalence of hidradenititis suppurativa

Hidradenitis suppurativa was long thought to be a rare condition, but global data put the prevalence at 1%, says Naik, co-chair of the new AAD-HS Foundation guidelines for the disease.

Advertisement
Advertisement

Official Media Partners